Loading…
Apogee Therapeutics, Inc. is projected to rise to $197.75 by 2027, a +48% move from its current price of $133.65. APGE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $130.21 | $133.68 | $137.25 | +0.02% |
| Jul 15 | $128.83 | $133.71 | $138.78 | +0.05% |
| Jul 16 | $127.79 | $133.74 | $139.98 | +0.07% |
| Jul 17 | $126.92 | $133.78 | $141.00 | +0.09% |
| Jul 18 | $126.16 | $133.81 | $141.92 | +0.12% |
| Jul 19 | $125.49 | $133.84 | $142.75 | +0.14% |
| Jul 20 | $124.87 | $133.87 | $143.52 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $124.87 | $133.87 | $143.52 | +0.17% |
| Week 2 | $121.52 | $134.09 | $147.96 | +0.33% |
| Week 3 | $119.06 | $134.32 | $151.53 | +0.50% |
| Week 4 | $117.05 | $134.54 | $154.63 | +0.66% |
| Week 5 | $115.34 | $134.76 | $157.46 | +0.83% |
| Week 6 | $113.82 | $134.98 | $160.08 | +1.00% |
| Week 7 | $112.47 | $135.21 | $162.55 | +1.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Apogee Therapeutics, Inc. is a clinical stage biotechnology company focused on developing novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. It develops Zumilokibart (APG777), a subcutaneous extended half-life monoclonal antibody for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial.
It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
APGE is a healthcare stock with a current price of $132.55 and a market cap of $9.97B, ranking 878. The near-term technical setup shows resistance at $132.55 and support at $77.75 with a 30-day price range of $102.22 to $171.88. The longer-term outlook remains bullish across multiple forecast years, reflecting upside potential embedded in the projected price trajectory.
A major floor 55.7% below — a decisive break under it would weaken the trend.
The nearest floor, 41.8% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 27.8% above — clearing it would confirm fresh momentum.
Key APGE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of APGE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $133.50 | Buy | $133.28 | Buy |
| MA 10 | $133.11 | Buy | $130.46 | Buy |
| MA 20 | $119.50 | Buy | $121.35 | Buy |
| MA 50 | $97.23 | Buy | $104.58 | Buy |
| MA 100 | $87.66 | Buy | $92.35 | Buy |
| MA 200 | $76.06 | Buy | $79.16 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 81.19 | Sell |
| Stoch RSI (14) | 34.76 | Neutral |
| CCI (20) | 49.94 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | -0.07 | Sell |
| ROC (12) | 0.58 | Buy |
| Bollinger %B (20,2) | 0.67 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 1.83 | Buy |
| Awesome (5,34) | 29.24 | Buy |
| Ultimate (7,14,28) | 85.57 | Sell |
| Momentum (10) | 0.97 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 133.69 | Sell |
| ADX (14) | 44.23 | Buy |
| ATR (14) | 2.18 | Info |
The 30-day technical picture is bullish overall. RSI(14) is 80, and the price has been trading above the SMA50 of $85.68 and the SMA200 of $69.85.
Near-term resistance is at $132.55 and support sits at $77.75. The 30-day price range is $102.22 to $171.88, and annualized volatility stands at 80.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $62.13 | $133.65 | $183.28 | 0% | Neutral | |
| $157.97 | $197.75 | $261.57 | +48% | Bullish | |
| $200.05 | $257.22 | $352.62 | +92% | Bullish | |
| $222.48 | $292.48 | $412.36 | +119% | Bullish | |
| $260.87 | $349.71 | $504.84 | +162% | Bullish | |
| $274.84 | $375.06 | $552.70 | +181% | Bullish | |
| $289.21 | $401.27 | $602.36 | +200% | Bullish | |
| $353.99 | $498.83 | $761.49 | +273% | Bullish | |
| $423.23 | $605.26 | $938.32 | +353% | Bullish | |
| $480.27 | $696.59 | $1,095.49 | +421% | Bullish | |
| $682.46 | $1,055.08 | $1,762.10 | +689% | Bullish | |
| $1,385.94 | $2,390.33 | $4,358.25 | +16.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $62.13 | $133.65 | $161.90 | +0.00% |
| August 2026 | $114.71 | $135.25 | $163.65 | +1.20% |
| September 2026 | $115.04 | $136.56 | $167.02 | +0.97% |
| October 2026 | $120.45 | $143.81 | $177.48 | +5.31% |
| November 2026 | $122.95 | $147.52 | $183.45 | +2.58% |
| December 2026 | $121.44 | $146.37 | $183.28 | -0.78% |
Click any year to see its month-by-month APGE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The APGE price prediction for 2026 points to an average of $133.65 (low $62.13, high $183.28) — a potential gain of 0% on today's $133.65. Price action looks broadly range-bound.
In 2027, APGE is projected to trade between $157.97 and $261.57, averaging $197.75 — a potential gain of +48% from today's $133.65. That is up +48% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Apogee Therapeutics, Inc.'s 2028 outlook centres on $257.22, within a $200.05 to $352.62 range. That is up +30% on the projected 2027 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2029, APGE could reach as high as $412.36, with a base case around $292.48 and support toward $222.48 — roughly +119% from $133.65. Buyers look set to stay in control over this stretch.
Expect APGE to range from $260.87 to $504.84 through 2030. The $349.71 average target implies a +162% move from current prices. That is up +20% on the projected 2029 average. Momentum favours further upside here.
The APGE price prediction for 2031 points to an average of $375.06 (low $274.84, high $552.70) — a potential gain of +181% on today's $133.65. Buyers look set to stay in control over this stretch.
In 2032, APGE is projected to trade between $289.21 and $602.36, averaging $401.27 — a potential gain of +200% from today's $133.65. That is up +7% on the projected 2031 average. Momentum favours further upside here.
Apogee Therapeutics, Inc.'s 2033 outlook centres on $498.83, within a $353.99 to $761.49 range. That is up +24% on the projected 2032 average. That marks a +273% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, APGE could reach as high as $938.32, with a base case around $605.26 and support toward $423.23 — roughly +353% from $133.65. Momentum favours further upside here.
Expect APGE to range from $480.27 to $1,095.49 through 2035. The $696.59 average target implies a +421% move from current prices. That is up +15% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The APGE price prediction for 2040 points to an average of $1,055.08 (low $682.46, high $1,762.10) — a potential gain of +689% on today's $133.65. Momentum favours further upside here.
In 2050, APGE is projected to trade between $1,385.94 and $4,358.25, averaging $2,390.33 — a potential gain of +16.9x from today's $133.65. That is up +127% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in APGE today (≈ 7.48223 APGE) could be worth
$17,884.96
+$16,884.96 (+1688%) by 2050 · US Dollar
Based on the average projected APGE price of $2,390.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in APGEwould be worth at today's price.
$1,000 invested in APGE on Jul 10, 2025 (≈ 25.926886 APGE) would be worth
$3,465.13
+$2,465.13 (+246.5%) today · 3.47× · US Dollar
Based on a APGE entry price of $38.57 vs. today's $133.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $132.91 | $1,005.57 | +0.6% |
| 1 month ago | $82.72 | $1,615.69 | +61.6% |
| 3 months ago | $86.27 | $1,549.21 | +54.9% |
| 6 months ago | $77.65 | $1,721.18 | +72.1% |
| 1 year ago | $38.57 | $3,465.13 | +246.5% |
| All time (3.0y) ago | $21.23 | $6,295.34 | +529.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our APGE forecast.
Our base-case forecast reaches $270.00 around 2029.
Implied market cap at $270.00: $16.66B
The multi-year forecast shows strong upside. For 2026 the avg price is $132.55 with min $62.13 and max $190.02, and an ROI of 0 with a NEUTRAL sentiment. From 2027 onward, the forecast turns bullish, with 2027 avg $210.84, 2028 avg $273.38, 2029 avg $303.79, and 2030 avg $366.21 (min $250.13, max $581.31; ROI 176.3).
The 2040 forecast shows avg $1,006.67 with min $538.56 and max $1,938.58 (ROI 659.5), and the 2050 forecast shows avg $2,305.87 with min $1,037.64 and max $4,969.05 (ROI 1639.6). Across these years the sentiment is BULLISH.
Tap a question to reveal the answer.
2030 avg $366.21; min $250.13; max $581.31; ROI 176.3; sentiment BULLISH.
The forecast shows NEUTRAL sentiment in 2026 with avg $132.55 and rises to BULLISH in 2027 and beyond, with rising avg values such as 2027 $210.84, 2028 $273.38, and 2029 $303.79.
Yes: 2040 avg $1,006.67; min $538.56; max $1,938.58; ROI 659.5; sentiment BULLISH.
2050 avg $2,305.87; min $1,037.64; max $4,969.05; ROI 1639.6; sentiment BULLISH.
Current price $132.55; Market cap $9.97B.
Apogee Therapeutics, Inc. Community Discussion
0Share your Apogee Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.